INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 92 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2015. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,299,513 | -51.4% | 44,145 | -40.9% | 0.00% | -50.0% |
| Q2 2023 | $4,729,877 | +119.6% | 74,698 | +87.8% | 0.00% | +100.0% |
| Q1 2023 | $2,153,763 | +40.6% | 39,774 | +37.4% | 0.00% | 0.0% |
| Q4 2022 | $1,532,299 | +1166.4% | 28,955 | +1011.1% | 0.00% | – |
| Q3 2022 | $121,000 | -40.4% | 2,606 | -26.6% | 0.00% | – |
| Q2 2022 | $203,000 | -94.6% | 3,549 | -94.2% | 0.00% | -100.0% |
| Q1 2022 | $3,746,000 | +77.0% | 61,220 | +51.4% | 0.00% | 0.0% |
| Q4 2021 | $2,116,000 | +1592.8% | 40,448 | +1107.4% | 0.00% | – |
| Q3 2021 | $125,000 | -76.4% | 3,350 | -74.1% | 0.00% | – |
| Q2 2021 | $529,000 | -20.0% | 12,958 | -33.4% | 0.00% | – |
| Q1 2021 | $661,000 | +6.3% | 19,462 | -0.6% | 0.00% | – |
| Q4 2020 | $622,000 | +475.9% | 19,586 | +366.3% | 0.00% | – |
| Q3 2020 | $108,000 | -79.2% | 4,200 | -79.2% | 0.00% | – |
| Q2 2020 | $518,000 | -32.6% | 20,201 | -59.6% | 0.00% | – |
| Q1 2020 | $768,000 | -69.2% | 49,995 | -31.2% | 0.00% | -100.0% |
| Q4 2019 | $2,492,000 | +4601.9% | 72,617 | +922.8% | 0.00% | – |
| Q3 2019 | $53,000 | -51.4% | 7,100 | -15.5% | 0.00% | – |
| Q2 2019 | $109,000 | -24.8% | 8,400 | -29.3% | 0.00% | – |
| Q1 2019 | $145,000 | +39.4% | 11,889 | +30.0% | 0.00% | – |
| Q4 2018 | $104,000 | +700.0% | 9,146 | +1424.3% | 0.00% | – |
| Q3 2018 | $13,000 | -7.1% | 600 | -21.9% | 0.00% | – |
| Q2 2018 | $14,000 | -65.9% | 768 | -60.8% | 0.00% | – |
| Q1 2018 | $41,000 | +355.6% | 1,961 | +226.8% | 0.00% | – |
| Q4 2017 | $9,000 | -94.9% | 600 | -94.6% | 0.00% | – |
| Q3 2017 | $177,000 | +0.6% | 11,160 | -21.5% | 0.00% | – |
| Q2 2017 | $176,000 | +8700.0% | 14,224 | +14124.0% | 0.00% | – |
| Q1 2017 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | -97.8% | 100 | -98.4% | 0.00% | – |
| Q3 2016 | $93,000 | -88.6% | 6,064 | -71.0% | 0.00% | – |
| Q2 2016 | $813,000 | +3595.5% | 20,935 | +2516.9% | 0.00% | – |
| Q1 2016 | $22,000 | -78.0% | 800 | -56.6% | 0.00% | – |
| Q4 2015 | $100,000 | +525.0% | 1,842 | +360.5% | 0.00% | – |
| Q3 2015 | $16,000 | -82.4% | 400 | -85.9% | 0.00% | – |
| Q2 2015 | $91,000 | +279.2% | 2,836 | +184.2% | 0.00% | – |
| Q1 2015 | $24,000 | +4.3% | 998 | -22.9% | 0.00% | – |
| Q4 2014 | $23,000 | – | 1,294 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |